United Therapeutics Corporation ($UTHR) Stock Forecast: Up 9.7% Today

What is United Therapeutics Corporation?

United Therapeutics (UTHR) is a biotechnology company that specializes in developing and selling innovative products for patients with chronic and life-threatening conditions. The overall market sentiment towards UTHR has been positive recently.

Why is United Therapeutics Corporation going up?

UTHR stock is up 9.7% on Oct 29, 2025 17:40

• UTHR stock showed a strong bullish movement today, likely influenced by the company surpassing Q3 earnings expectations.
• Despite revenues falling below projections, the robust performance of Tyvaso and Orenitram contributed to the positive earnings surprise.
• Investor optimism regarding potential growth opportunities in the coming quarters may be fueled by the earnings beat.
• Market trends indicate that investors are more focused on the positive earnings surprise and growth potential, overshadowing the revenue shortfall and driving the bullish momentum in UTHR stock.

UTHR Price Chart

UTHR Technical Analysis

UTHR News

United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark

UTHR beats Q3 earnings forecasts on solid Tyvaso and Orenitram growth, while revenues fall shy of estimates.

https://www.zacks.com/stock/news/2780414/united-therapeutics-q3-earnings-beat-estimates-revenues-miss-mark

United Therapeutics ( UTHR ) Beats Q3 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of +3.92% and -2.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2779808/united-therapeutics-uthr-beats-q3-earnings-estimates

Trending Today

Hedera Hashgraph ($HBAR) Crypto Forecast: Up 5.0% Today

Soybeans ($SOY) Commodity Forecast: Down 0.4% Today

ZCash ($ZEC) Crypto Forecast: Up 11.6% Today

Duolingo Inc. ($DUOL) Stock Forecast: Down 6.9% Today

Centene Corporation ($CNC) Stock Forecast: Up 12.8% Today

American Electric Power Company Inc. ($AEP) Stock Forecast: Up 6.2% Today

DaVita Inc. ($DVA) Stock Forecast: Down 1.9% Today

Garmin Ltd. ($GRMN) Stock Forecast: Down 11.7% Today

Fiserv Inc. ($FI) Stock Forecast: Down 43.9% Today

PayPal Holdings Inc. ($PYPL) Stock Forecast: Down 5.3% Today

United Therapeutics Corporation Price History

26.01.2025 - UTHR Stock was down 8.1%

• Despite United Therapeutics surpassing Q4 earnings and revenue estimates, the stock experienced a bearish movement, indicating that the market may have had higher expectations.
• Investors might have been disappointed with the company's future guidance or outlook, leading to a sell-off of the stock.
• The market may have reacted negatively to key metrics that fell short of Wall Street projections, causing a decline in UTHR's stock price.

09.03.2025 - UTHR Stock was down 5.7%

• Despite the positive market sentiment and expectations of a strong performance in the upcoming period, UTHR faced significant bearish movement today.
• This unexpected downturn may be linked to investors taking profits, potentially motivated by the anticipation of positive earnings.
• Market dynamics or external factors could have also played a role in the stock's decline, counter to the optimistic outlook for UTHR's future earnings.

07.04.2025 - UTHR Stock was up 5.2%

• A dispute filed by United Therapeutics against Liquidia was dismissed by the District Court.
• UTHR's Q1 earnings and revenues exceeded estimates, driven by increased Tyvaso sales.
• The favorable legal outcome and strong financial results are believed to have influenced the bullish movement in UTHR's stock price today.

01.07.2025 - UTHR Stock was up 5.1%

• The reasons for the bullish movement in UTHR stock are:
• Strong Tyvaso sales contributing to a 12% increase in revenues year-over-year.
• Despite missing earnings estimates for the second quarter, the market reacted positively to the company's revenue growth.
• The announcement of a share repurchase program of up to $1 billion by the company's board may have instilled confidence in investors concerning future prospects.
• Investors seem to be concentrating more on the revenue growth and potential of the company's product portfolio rather than short-term earnings misses.

12.01.2025 - UTHR Stock was up 1.2%

• The positive movement in UTHR today could stem from favorable market sentiment towards the company's recent product advancements or financial performance.
• Comparisons made between UTHR and ZTS may have played a role in boosting investor trust in UTHR, potentially positioning UTHR as an appealing investment choice.
• Investors may have viewed UTHR as a more attractive stock in terms of value compared to ZTS, leading to increased buying interest and driving up the stock price.
• In summary, today's uptick in UTHR may be a result of internal company factors as well as evaluations against industry peers in the biotechnology field.

02.08.2025 - UTHR Stock was up 0.8%

• Following the announcement of an expanded collaboration with MannKind Corporation for a second inhaled therapy, United Therapeutics (UTHR) witnessed a notable increase in its stock price. This development likely instilled confidence in investors regarding the company's growth potential and the possibility of new revenue streams.
• The positive market response could also be linked to the upcoming earnings report of United Therapeutics, adding to the optimistic outlook for the company's financial performance. As the stock continues to rise, investors appear hopeful about its future prospects.
• Today's bullish movement in UTHR's stock reflects the favorable progress in collaboration initiatives and the market's optimistic view of the company's future in the pharmaceutical sector.

30.06.2025 - UTHR Stock was down 5.4%

• UTHR reported Q2 earnings that missed analyst estimates on both the top and bottom lines, leading to a bearish movement in the stock.
• The company's announcement of a share repurchase program of up to $1 billion did not seem to offset the disappointment from the earnings miss.
• The stock crossing above the 50-day moving average could have initially signaled a positive trend, but the earnings results likely overshadowed this technical indicator, causing the bearish movement.
• Investors may be concerned about the company's future performance based on the Q2 results, leading to a sell-off in the stock.

29.09.2025 - UTHR Stock was up 8.3%

• UTHR experienced a strong bullish movement today by surpassing Q3 earnings estimates, exceeding expectations by 3.92%.
• The anticipation of earnings growth leading up to the upcoming report has likely bolstered the positive sentiment, showcasing faith in the company's future performance.
• Investors appear hopeful about UTHR's prospects, given its consistent delivery of favorable outcomes and ability to meet market expectations, resulting in an increase in the stock price.

10.05.2025 - UTHR Stock was down 10.7%

• UTHR's bearish movement could be attributed to profit-taking by investors after a period of growth or due to concerns about the company's future performance.
• The potential struggles of Corcept (CORT) after their last earnings report may have had a spillover effect on UTHR, causing investors to be cautious about the biotechnology sector as a whole.
• Investors might be reevaluating their positions in biotech stocks, leading to a broader sell-off in the sector and impacting UTHR negatively.
• It is essential for investors to closely monitor both company-specific news and industry trends to make informed decisions in the volatile biotechnology market.

30.06.2025 - UTHR Stock was down 4.2%

• UTHR stock witnessed a significant decline in value today.
• Falling short of Q2 earnings estimates by -5.74% potentially influenced the downward trajectory.
• Although surpassing the 50-day moving average, investors' response to the earnings disappointment likely drove the negative trend.
• Investor sentiment concerning UTHR may be influenced by apprehensions regarding future performance following the recent earnings outcome.

30.03.2025 - UTHR Stock was up 2.1%

• UTHR's strong bullish movement today can be attributed to the company's impressive Q1 earnings and revenue results, surpassing analyst estimates by 5.41% and 9.39% respectively. This positive financial performance likely instilled confidence in investors, driving up the stock price.
• Despite the overall bullish market movement, it's interesting to note that there were downgrades from a top analyst, which could have initially caused some uncertainty. However, the market seemed to focus more on the robust earnings report, overshadowing the analyst's revised outlook.
• The market's reaction indicates that investors placed more weight on UTHR's solid financial fundamentals rather than the analyst's downgrade, showcasing the significance of strong earnings in influencing stock price movements.

29.09.2025 - UTHR Stock was up 9.7%

• UTHR stock showed a strong bullish movement today, likely influenced by the company surpassing Q3 earnings expectations.
• Despite revenues falling below projections, the robust performance of Tyvaso and Orenitram contributed to the positive earnings surprise.
• Investor optimism regarding potential growth opportunities in the coming quarters may be fueled by the earnings beat.
• Market trends indicate that investors are more focused on the positive earnings surprise and growth potential, overshadowing the revenue shortfall and driving the bullish momentum in UTHR stock.